{'fraction_non_alphanumeric': 0.0289193302891933, 'fraction_numerical': 0.0060882800608828, 'mean_word_length': 6.230769230769231, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Lipoprotein‐associated phospholipase A2 and cardiovascular disease risk in HIV infection

HIV‐infected patients on antiretroviral therapy (ART) have an increased cardiovascular disease (CVD) risk as a result of heightened inflammation and immune activation, despite at times having normal lipids and few traditional risk factors. Biomarkers are needed to identify such patients before a clinical event. Lipoprotein‐associated phospholipase A2 (Lp‐PLA2) predicts CVD events in the general population. This study investigated the relationship between Lp‐PLA2 and markers of CVD risk, systemic inflammation, immune activation, and coagulation in HIV infection.